Abstract
The article presents up-to-date data on the pathogenesis, classification and frequency of ophthalmic extraintestinal manifestations (OEM) of inflammatory bowel diseases (IBD). Early detection of OEM is an important aspect of the management of IBD patients, since timely and effective therapy of combined immuno-inflammatory pathology has a positive effect on the prognosis of the disease and reduces the disability of IBD patients. The article provides information on methods of diagnostic of ophthalmic manifestations of IBD and treatment of patients with combined immuno-inflammatory pathology. The close interaction of gastroenterologists and ophthalmologists is an important link in the implementation of multidisciplinary management of patients with IBD and autoimmune uveitis. The use of genetically engineered biological drugs helps to control the course of IBD and ophthalmic manifestations, which prevents the development of complications and improves the quality of life of patients
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
